Summary:
The efficacy of methotrexate (MTX) as a single graft-versus-host disease (GVHD) prophylaxis agent was compared to that of cyclosporin A (CSA) in 62 pediatric patients (median age: 8 years) with hematological malignancies who had undergone bone marrow transplantation (BMT) from HLA-identical sibling donors at National Kyushu Cancer Center since 1977. In all, 30 patients received MTX by intravenous bolus injection, with a dose of 15 mg/m2 on day +1, followed by 10 mg/m2 on days +3, +6, and +11, and then once a week until day +100. A total of 32 patients were treated with CSA, which was given intravenously in the early stages and orally thereafter until day +100, and then gradually tapered and stopped 6 months after BMT. There were no differences between the groups in terms of rates of hematopoietic recovery after BMT. The probabilities of acute GVHD (grades II–IV) and chronic GVHD were 29.6 vs 40.6% (P=0.294) and 19 vs 20% (MTX vs CSA), respectively. Relapse rates and event-free survival were identical. These results suggest that MTX and CSA were equally effective when given after BMT in Japanese pediatric patients with hematological malignancies. Since MTX was given over a shorter time than CSA, it might be more practical in the management of such patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Goker H, Haznedaroglue IC, Chao NJ . Acute graft-versus-host disease: Pathophysiology and management. Exp Hematol 2001; 29: 259–277.
Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclo-sporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.
Hiraoka A, Ohashi Y, Okamoto S et al. Phase II study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 181–185.
Ringden O, Horowitz MM, Sondel P et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia. Blood 1993; 81: 1094–1101.
Locatelli F, Zecca M, Rondelli R et al. Graft versus host disease prophylaxis with low-dose cyclosporin-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572–1579.
Storb R, Epstein RB, Graham TC et al. Methotrexate regimens for control of graft-versus host disease in dogs with allogeneic marrow grafts. Transplantation 1970; 9: 240–246.
Deeg HJ, Storb R, Thomas ED et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985; 65: 1325–1334.
Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.
Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host disease syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
Thomas E, Storb R, Clift RA et al. Bone marrow transplantation. N Engl J Med 1975; 292: 832–843.
Deeg HJ, Storb R . Graft-versus-host disease: pathophysio-logical and clinical aspects. Ann Rev Med 1984; 35: 11–24.
Maruya E, Saji H, Seki S et al. Evidence that CD31, CD49b, and Cd62L are immunodominant minor histocompatibility antigens in HLA-identical sibling bone marrow transplants. Blood 1998; 92: 2169–2176.
Storb R, Deeg HJ, Fisher L et al. Cyclosporin vs methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988; 71: 293–298.
Teshima T, Ferrara JL . Understanding the allo response: New approaches to graft-versus-host disease prevention. Semin Hematol 2002; 39: 12–22.
Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
Ratanatharathorn V, Nash RA, Pzepiorka D et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303–2314.
Yanik G, Levine JE, Ratanatharathorn V et al. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplant-ation. Bone Marrow Transplant 2000; 26: 161–167.
Storb HJ, Deeg ED, Thomas et al. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 1985; 66: 698–702.
Peter C, Minkov M, Gadner H et al. Statement of current majority practice in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 2000; 26: 405–411.
Acknowledgements
We are grateful to the nursing staff at National Kyushu Cancer Center during the study period. We thank the resident doctors for their contribution in caring for the transplanted patients.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koga, Y., Nagatoshi, Y., Kawano, Y. et al. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan. Bone Marrow Transplant 32, 171–176 (2003). https://doi.org/10.1038/sj.bmt.1704051
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704051
Keywords
This article is cited by
-
Superior outcome using cyclosporin A alone versus cyclosporin A plus methotrexate for post-transplant immunosuppression in children with acute leukemia undergoing sibling hematopoietic stem cell transplantation
Journal of Cancer Research and Clinical Oncology (2015)
-
Prophylactic and therapeutic treatment of graft-versus-host disease in Japan
International Journal of Hematology (2015)
-
Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease
International Journal of Hematology (2008)
-
Chronic graft-versus-host disease: where is promise for the future?
Leukemia (2005)
-
Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2005)